Welcome to our dedicated page for Iperionx SEC filings (Ticker: IPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The IperionX Limited (IPX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. IperionX files annual reports on Form 20-F and furnishes current information on Form 6-K, including quarterly reports, sustainability reports, notices of annual general meeting, trading halt requests and press releases related to its titanium and critical minerals operations.
Through these filings, investors can review how IperionX describes its business as an American titanium metal and critical materials company that uses patented technologies to produce high performance titanium alloys from titanium minerals or scrap titanium. Annual and quarterly reports furnished as exhibits to Form 6-K outline the status of the Titanium Manufacturing Campus in Virginia, the Titan Critical Minerals Project in Tennessee, government funding arrangements, customer programs and risk factors associated with scaling titanium production and commercialization.
Filings also document U.S. Government support, including Defense Production Act Title III investments, Industrial Base Analysis and Sustainment awards, and the Small Business Innovation Research (SBIR) Phase III Indefinite Delivery, Indefinite Quantity contract that enables task orders for titanium components. These documents provide detail on how such programs are structured and how they relate to IperionX’s plans to expand titanium capacity and develop a mineral-to-metal supply chain.
On Stock Titan, users can view these SEC submissions as they are furnished to EDGAR and use AI-powered summaries to interpret complex sections. The platform highlights key elements of IperionX’s 20-F and 6-K exhibits, helping readers quickly understand disclosures about production capacity, government contracts, critical minerals resources, financial reporting practices and other material information contained in the company’s official filings.
IPERIONX Ltd Executive Chairman Todd Hannigan received new equity awards in the form of performance rights and options linked to IPX Ordinary Shares. On April 2, 2026, he was granted 196,086 performance rights and 465,410 options each with an exercise price of A$18.00, plus 526,760 options with an exercise price of A$22.00.
Each performance right can convert into one ordinary share if service and stock price performance conditions are met, and each option allows purchase of one ordinary share at the stated price. Following these awards, he holds 25,628,334 Ordinary Shares directly, alongside existing derivative positions and 500,000 ADS representing IPX Ordinary Shares.
IPERIONX Ltd President Toby Edgcumbe Symonds made an open‑market purchase of 11,000 American Depository Shares (ADS) of IPERIONX at an average price of $23.8684 per ADS. Each ADS represents 10 ordinary shares traded on the Australian Stock Exchange.
After this transaction, he directly holds 11,000 ADS, 3,188,146 ordinary shares, and 703,199 Restricted Stock Units. He also holds performance rights over ordinary shares with exercise prices of A$4, A$6, A$7 and A$8, exercisable or expiring between December 2028 and April 2030.
IPERIONX Ltd director R. Tony Tripeny bought shares on the open market. He purchased 4,187 American Depository Shares at an average price of $23.7554 per ADS in an open‑market transaction. Following this purchase, he directly holds 4,187 ADS, 38,777 ordinary shares, and 51,010 restricted stock units. One ADS is convertible into 10 ordinary shares, and the RSUs are scheduled to vest in tranches of 36,848 in December 2026 and 14,162 in December 2027.
IPERIONX Ltd director Hannigan Todd made an open-market purchase of 225,225 Ordinary Shares at $3.2009 per share. After this transaction, he directly holds 25,628,334 Ordinary Shares.
He also holds performance rights over 306,302 underlying Ordinary Shares at each of A$6, A$7 and A$8 exercise prices, plus 454,464 Restricted Stock Units and 50,000 American Depository Shares, where each ADS is convertible into 10 Ordinary Shares.
IPERIONX Ltd Chief Executive Officer Arima Anastasios reported significant open-market share purchases. On March 27, 2026, he bought 467,000 Ordinary Shares at an average price of A$3.198, taking his direct Ordinary Share holdings to 12,206,782.
On the same date, he also bought 12,800 American Depository Shares (ADS) at an average price of $23.4097, and now holds 12,800 ADS directly. Each ADS represents 10 Ordinary Shares.
He also holds Performance Rights over 435,806 underlying Ordinary Shares at each of A$6, A$7, and A$8, all expiring on April 10, 2030, plus 738,576 Restricted Stock Units, with 318,666 vesting in December 2026 and 419,910 in April 2028.
IPERIONX Ltd President Toby Symonds has filed an initial ownership report detailing his equity and incentive holdings. He directly holds 3,128,089 Ordinary Shares traded on the ASX and 23,000 American Depository Shares listed on NASDAQ, with each ADS representing 10 ordinary shares.
He also holds 703,199 Restricted Stock Units, with 302,666 vesting in December 2026 and 400,533 vesting in April 2028. In addition, he has Performance Rights over 1,110,000 underlying Ordinary Shares at A$4 expiring on December 21, 2028, and 415,695 underlying shares at each of A$6, A$7, and A$8 exercise prices, all expiring on April 10, 2029.
IPERIONX Ltd director Hannigan Todd has filed an initial Form 3 reporting his existing equity interests in the company. The filing lists direct ownership of 25,403,109 Ordinary Shares, 454,464 Restricted Stock Units, and 50,000 American Depository Shares, each ADS representing ten Ordinary Shares traded on NASDAQ.
He also holds performance rights over 306,302 underlying IPX Ordinary Shares at each of A$6, A$7, and A$8 exercise prices, expiring in April 2030. Footnotes state that 159,334 units vest in December 2026 and 295,130 vest in April 2028, highlighting a structured, long-term incentive position rather than new market transactions.
IPERIONX Ltd Chief Executive Officer Anastasios Arima reports his existing equity stake in the company. He directly holds 11,739,782 Ordinary Shares, which trade on the Australian Securities Exchange. He also holds 738,576 Restricted Stock Units, with portions vesting in December 2026 and April 2028.
In addition, Arima holds three tranches of performance rights over IPX Ordinary Shares, each covering 435,806 underlying shares with exercise prices of A$6, A$7, and A$8. These performance rights are exercisable from April 2029 and expire in April 2030, providing potential future share issuance tied to performance conditions.
IperionX Limited held a General Meeting on March 19, 2026, where shareholders approved four resolutions granting long-term equity incentives to founder executives Anastasios Arima (CEO) and Todd Hannigan (Executive Chair). All resolutions were carried by poll, with support ranging from about 82% to 95% of votes cast.
Shareholders approved up to 1,203,964 Options and 237,944 Performance Rights for Mr. Arima, and up to 992,170 Options and 196,086 Performance Rights for Mr. Hannigan. Option strike prices of A$18 and A$22 and a Performance Rights hurdle of a 30‑day VWAP of A$18 sit well above the A$6.76 share price on February 2, 2026, so value only arises if the share price increases substantially.
The company explains that executive pay is benchmarked to U.S. peers, reflecting its U.S.-based titanium technology and manufacturing focus. The awards have four‑year service requirements, five‑year terms, and, for Performance Rights, an additional one‑year lock‑up, aiming to link executive rewards to long-term shareholder value creation.
IPERIONX Ltd director Taylor Vaughn William has filed an initial ownership report showing direct holdings of 973,457 Ordinary Shares and 84,771 Restricted Stock Units. Footnotes state that 70,609 RSUs vest in December 2026 and 14,162 vest in December 2027, and that Ordinary Shares trade on the ASX.